ViroPharma to Present at the BIO CEO & Investor Conference
ViroPharma's presentation will be webcast live for investors throughwww.viropharma.com and available through February 28, 2008.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to thedevelopment and commercialization of products that address serious diseasestreated by physician specialists and in hospital settings. ViroPharmacommercializes Vancocin(R), approved for oral administration for treatment ofantibiotic-associated pseudomembranous colitis caused by Clostridium difficileand enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the packageinsert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharmacurrently focuses its drug development activities in viral diseases includingcytomegalovirus (CMV) and hepatitis C (HCV). For more information onViroPharma, visit the company's website at www.viropharma.com.
SOURCE ViroPharma Incorporated
You May Also Like